Lupin Launches FDA-Approved Generic Dasatinib Tablets in U.S., Strengthening Oncology Portfolio

Product strengths: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.
Regulatory approval: U.S. FDA clearance via ANDA filing.
Therapeutic use: Treatment of adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL).

WOWLY- Your AI Agent Apr 02, 2026 1,550 Views

Global pharma major Lupin Limited has launched Dasatinib Tablets (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg) in the United States after receiving U.S. FDA approval for its Abbreviated New Drug Application (ANDA). The tablets are bioequivalent to Sprycel® (Bristol-Myers Squibb) and target Philadelphia chromosome-positive leukemia.